Childhood cancer is relatively rare, representing only about 1% of all malignant disease. However, the number of children with cancer in the world is expected to increase in parallel with the global population. Of the estimated 250 000 children diagnosed with cancer every year, about 200 000 live in countries with limited resources; their survival rate is estimated to be 25%, while in developed countries it approximates 80%.1

It is estimated that there are 50 000 new cases of childhood cancer every year in Africa.2 In countries bordering the Mediterranean sea and in South Africa (SA) leukemias are the most frequent cancers in children, while in sub-Saharan Africa lymphomas are predominant, with Burkitt’s lymphoma (BL) the most common.2-3 Data on survival rates in Africa are scarce and the available information is not reassuring. Published 5-year survival rates for BL vary from 5% to 70%,4 with most countries falling within the lower half of the range.

All efforts to improve outcomes in childhood cancer should be based on a comprehensive and reliable statistical analysis of the situation. In the absence of national cancer registries, let alone national paediatric cancer registries (South Africa has the only such registry on the continent5), hospital registries may provide the required information.

The aim of this study was to analyse the data entered in the register of the paediatric haematology oncology unit in Treichville, Côte d’Ivoire, from January 1995 to December 2004, as a starting point for establishing a strategy to improve the situation of paediatric oncology and to evaluate progress over time. The information was grouped under patient demographics, types of pathology, delay in diagnosis and treatment, modalities of treatment, abandonment of treatment and survival rate.

Côte d’Ivoire is a Francophone African country situated on the western part of the continent, with a population of more than 20 million. Children (under 18 years of age) represent 45% of the population. About 43% of all inhabitants live below the poverty line, with the annual gross domestic product per capita being US$1 600.7 There are 14 doctors per 100 000 people.8 Abidjan, with a population of 3 310 500, is Côte d’Ivoire’s largest city and commercial and banking centre.

The haematology oncology unit of the Department of Paediatrics was set up in Treichville (a commune of Abidjan) in 1995. It has 20 beds and serves as the referral service for all children diagnosed with cancer in Côte d’Ivoire. It also receives patients from neighbouring countries (Mauritania, Senegal, Mali, Burkina Faso, Guinea and Liberia). The service has a radiology facility including a computed tomography (CT) scanner and a paediatric surgery division. Not all cases of childhood cancer over the study period were histologically confirmed, as there were only

Background. There is insufficient research into the state of paediatric oncology in African countries.

Objectives. The purpose of this study was to analyse the state of paediatric oncology between 1995 and 2004 in Côte d’Ivoire.

Methods. This retrospective descriptive study analysed all patients under the age of 18 who were diagnosed with cancer in Côte d’Ivoire over a period of 10 years (January 1995 – December 2004) with regard to demographics, types of pathology, delay in diagnosis and treatment, treatment modalities, abandonment of treatment and survival rate.

Results. Of 405 patients diagnosed with cancer, 331 were included in the study. Burkitt’s lymphoma was the most common malignancy (73.6%), followed by nephroblastoma (14.5%) and acute leukaemia (4%). Delay in diagnosis occurred in 38.7% of cases and ranged from 1 to 3 months; the average delay from diagnosis to starting treatment was 18 days. An abdominal mass and swelling of the jaw were the most common clinical presentations. Almost half of the patients (48.6%) were lost to follow-up and over a third (39.3%) died shortly after admission owing to advanced disease. The overall survival rate was 9.4%.

Conclusions. Cancer in children in Côte d’Ivoire was dominated by Burkitt’s lymphoma. The rate of loss to follow-up of almost 50% is grounds for concern. The overall survival rate of 9.4% is very low, but such figures are not uncommon for African countries. Collaboration within the Franco-African Group of Paediatric Oncology has contributed to improving the management of children with cancer.
10 pathologists in the entire country and only 3 in the University Hospital of Treichville in Abidjan.

Chemotherapy was not freely available, the cost of management having to be borne by the patients’ families, who often could not afford to pay for either the investigations or the medication.

The time period analysed ends just before Treichville joined the GFAOP (Groupe Franco-Africain d'Oncologie Pédiatrique – Franco-African Group of Paediatric Oncology). Treichville became a therapy research unit after joining GFAOP, and results obtained after 2004 will constitute a comparative analysis.

Patients and methods
A retrospective descriptive study of the Treichville paediatric haematology oncology unit’s experience was undertaken. All records of children (0 - 18 years of age) admitted with a malignancy from 1 January 1995 to 31 December 2004 were reviewed. Of 405 patients who presented to the unit during this time period, 331 were included in the study (the remaining folders were incomplete or the diagnosis was not confirmed).

Variables analysed included age at diagnosis, gender, urban or rural area of residence, clinical presentation, stage of disease, delay in diagnosis (defined as the time interval from the onset of symptoms to diagnosis), delay in initiation of treatment following diagnosis, loss to follow-up, abandonment of therapy, therapeutic protocols and survival.

Staging of BL consisted of chest radiography, abdominal ultrasound, bone marrow aspiration (BMA) and trephine biopsy, together with laboratory investigations, including cerebrospinal fluid examination. Patients had CT scans and all cancers were confirmed by biopsy and histopathology.

Staging of nephroblastoma was based on abdominal ultrasound, intravenous pyelography and chest radiography.

In acute leukaemia, investigations undertaken included a full blood count with smear, BMA and trephine biopsy. Flow cytometry and cytogenetic studies were not available, nor were more sophisticated investigations such as magnetic resonance imaging, positron emission tomography or meta-iodobenzylguanidine scans.

Cure was defined as a remission lasting over 2 years (1 year for nephroblastoma).

Ethical approval for the study was obtained from the local ethics committee of the University Hospital of Treichville.

Results
The results of 331 children admitted with a malignancy during the study period were analysed. Of these, 244 (73.6%) were diagnosed with BL and presented with an abdominal mass, 48 patients with nephroblastoma (5.7%) constituted the second most common group, 13 patients (4.5%) were diagnosed with acute leukaemia, and 7 (2.1%) had Hodgkin’s disease. The remaining patients had retinoblastoma (6 cases), rhabdomyosarcoma (5 cases), neuroblastoma (3 cases), and sacrococcygeal teratoma, leiomyosarcoma, germ cell tumour, haemangiomata of the liver and undifferentiated abdominal sarcoma (1 case each).

The prevalence of childhood malignancies among the paediatric admissions at Treichville doubled over the study period, from 0.32% in 1995 to 0.76% in 2004. Table 1 describes the four most common malignancies in the study, which represent 96% of all cases.

The sex ratio was 1.35:1 (males 57%, females 43%). Most of the patients (78%) lived in urban areas and were between 5 and 10 years of age (mean 7.47 years). The most common clinical presentation was an abdominal mass (152 cases, 45.9%); 22 patients (6.6%) had both an abdominal mass and swelling of the jaw at presentation.

Only 76% of the patients received treatment. More than half (52.6%) of those who were not treated simply could not afford the costs, while the remainder died before treatment could be started. The chemotherapy protocol used for BL was COPAD modified,

<table>
<thead>
<tr>
<th>Variable</th>
<th>Burkitt's lymphoma</th>
<th>Nephroblastoma</th>
<th>Leukaemia</th>
<th>Hodgkin's lymphoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients, n (%)</td>
<td>244 (73.6)</td>
<td>48 (5.7)</td>
<td>13 (4.5)</td>
<td>7 (3.9)</td>
</tr>
<tr>
<td>Females, %</td>
<td>38.9</td>
<td>56.2</td>
<td>46.1</td>
<td>28.6</td>
</tr>
<tr>
<td>Males, %</td>
<td>61.1</td>
<td>43.7</td>
<td>53.8</td>
<td>71.4</td>
</tr>
<tr>
<td>Median age, years</td>
<td>7.4</td>
<td>4.1</td>
<td>10.2</td>
<td>8.4</td>
</tr>
<tr>
<td>Staging, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>14 (5.7)</td>
<td>0 (0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>12 (4.9)</td>
<td>8 (16.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>119 (48.8)</td>
<td>9 (18.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>25 (10.2)</td>
<td>2 (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>V</td>
<td>-</td>
<td>0 (0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not staged</td>
<td>74 (30.3)</td>
<td>29 (60.4)</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Outcome, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cured</td>
<td>6.6</td>
<td>27.1</td>
<td>7.7</td>
<td>0</td>
</tr>
<tr>
<td>Still treated</td>
<td>0.8</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>50</td>
<td>39.6</td>
<td>46.1</td>
<td>85.7</td>
</tr>
<tr>
<td>Relapsed</td>
<td>2</td>
<td>0</td>
<td>7.7</td>
<td>14.3</td>
</tr>
<tr>
<td>Died</td>
<td>40.6</td>
<td>33.3</td>
<td>38.5</td>
<td>0</td>
</tr>
</tbody>
</table>
consisting of cyclophosphamide 300 mg/m² on days 1, 2, 4 and 5, vincristine 1.5 mg/m² on days 3 and 6, adriamycin 50 mg/m² and prednisone 60 mg/m² on days 1 - 7, and methotrexate given intrathecally in a dose of 15 mg on days 1 and 7. Induction comprised 3 courses every 2 weeks or as soon as the blood count allowed administration of chemotherapy, with consolidation of 4 monthly courses. The treatment lasted 8 months and the patient was considered cured after achieving complete remission without a relapse for more than 2 years. Patients were followed up every 2 - 3 months during the first year after treatment was completed, every 6 months in the second year and then once a year. Almost half of the patients with BL died (40.6%), 50% were lost to follow-up, 2% relapsed and only 6.6% were considered cured (0.8% were still on treatment at the time of the study).

Of the patients with nephroblastoma, 22.9% had stage III or IV disease, and more than 60.5% were not staged. They were treated according to the SIOP 2001 protocol. Almost a third of the patients with nephroblastoma died, 39.6% were lost to follow-up, and 27.1% were still alive a year after treatment. In 61% of cases there was a delay in diagnosis of over 1 month. Therapy was instituted within 14 days in 59% of the children treated. Delays in commencing treatment were due to waiting for laboratory results or histological confirmation, and the families needing time to collect the money needed to pay for the chemotherapy.

Almost half of the patients were lost to follow-up after the first admission and 39.2% died shortly after the onset of treatment. Only 9.4% (31 patients) survived in remission for longer than 2 years, a small number suffered a relapse (2.1%), and 0.6% were still on treatment.

Discussion

The number of children with cancer increased in Côte d’Ivoire over the study period, mirroring experience in the rest of Africa and the world. Malignancy in children in West Africa remains dominated by BL and nephroblastoma. The survival rate for these two malignancies, which are easily diagnosed and respond to chemotherapy, exceeds 90% in developed countries. The 1-year survival rate for nephroblastoma in this study was 27.1%. The cost of treatment for both cancers is also relatively low compared with that of treating other malignancies: BL treatment costs around US$50 and the cost of treating stage 2 - 3 nephroblastoma, without radiotherapy, amounts to US$699.10

Other countries from sub-Saharan Africa report a distribution of malignant pathology in children similar to that described in this study. Lymphomas represented 41.2% of all malignancies in children at the University Teaching Hospital in Enugu, Nigeria, between 1999 and 2004;11 similarly, in the Tanzanian cancer registry between 1973 and 1995, lymphomas were the most frequent childhood malignancy at 38.9%.12 A different situation is reported from countries in northern Africa13 and SA,14 where childhood leukemias are most frequent.

In contrast to the major improvement in survival rates for childhood cancer in high-income countries and even in Africa,14 the overall survival rate for Ivorian children remained low over the period studied. However, marked increases in survival for children with cancer in low-resource settings have been achieved elsewhere. For instance, in most countries in Central America that have established twinning programmes and collaborative networks, the survival rate of children with acute lymphoblastic leukaemia has risen from less than 20% to over 60% over the past decade.15

The urban residence of over 75% of our patients, in contrast to an urbanisation level of around 40% for the Ivorian population as a whole, suggests that a number of children with cancer from rural areas did not reach the hospital in Treichville. Another major hurdle on the path to treatment was the need to pay for chemotherapy. This explains why a considerable number of patients were not treated, or abandoned their treatment. The need to raise money for treatment also contributed to the delay between diagnosis and the beginning of therapy. Similar effects of such economic constraints have been described in detail in a study from Nigeria.16

In 2004 the Paediatric Hematology Oncology Unit in Côte d’Ivoire joined the GFAO group.17 As a result, chemotherapy is now free of charge, treatment follows established protocols, and access to radiological investigations has been opened. This progress in management of paediatric malignancies will be the subject of a future study.

The present study makes available for the first time a synthesis of the data from the archives of the paediatric haematology oncology unit at the University Hospital of Treichville, Côte d’Ivoire. It contributes to completing the picture of the numerous challenges, many of them socio-economic, encountered in the management of children with cancer in Africa. Its main weakness, in common with all retrospective studies, is the often incomplete recording of data together with the loss of records of some patients.

Conclusions

During its first 10 years of existence, the paediatric haematology oncology unit at Treichville admitted more than 400 children with various malignancies from Côte d’Ivoire and surrounding countries. The most frequent diagnosis in these children was BL, followed by nephroblastoma. There was a high rate of abandonment of therapy, mainly for financial reasons, resulting in a low rate of cure of only 6.6% for BL and 27.1% for nephroblastoma (the latter at 1 year of follow-up). The unit’s collaboration with the GFAO in 2004 has resulted in a progressive improvement in patient management, and these more recent outcomes will be reviewed in a future study.

References